Compare ARK Genomic Revolution ETF (ARKG) vs General Mills, Inc. (GIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs General Mills, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while General Mills, Inc. trades at $36.26 (market cap $19.33B). The key difference: General Mills, Inc. pays a 6.74% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, General Mills, Inc. nearer its low. Which is the better fit depends on your goals.
| ARKG | GIS | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $43.57 | $51.60 |
52-Week Low | $23.09 | $32.17 |
Market Cap | — | $19.33B |
Enterprise Value | — | $32.82B |
Dividend Yield | — | 6.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
General Mills (GIS) trades at $36.22, up 1.03% on the day, near the analyst consensus price target of $36.14. The stock presents a mixed picture with a low P/E of 9.23 suggesting value, but profitability metrics like a negative net income margin and ROE for 2026 signal challenges. Recent Q2 2026 earnings beat expectations, yet the technical outlook is bearish, and news highlights sales pressure and a focus on cost savings to drive a margin recovery in fiscal 2027.
The investment outlook is cautious. The stock's low valuation and dividend yield offer potential value, but persistent sales softness, margin pressure from competition, and a high debt-to-asset ratio of 45% pose significant risks. Analyst sentiment is predominantly neutral to negative, with a majority hold rating, indicating a wait-and-see approach is warranted until clearer signs of sustainable growth emerge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
